Objective: To compare the work of breathing (WOB) in premature neonates supported with high-flow nasal cannula (HFNC) and nasal continuous positive airway pressure (NCPAP).
Introduction
Newborns with respiratory distress have been treated with supplemental oxygen for decades. Nasal continuous airway pressure (NCPAP) is used to support those infants with mild-tomoderate respiratory distress syndrome (RDS), those who have been extubated after treatment for RDS, those experiencing apnea of prematurity and those with other forms of respiratory distress soon after birth. 1 Its success has been attributed not only to respiratory support without the need for intubation 2 but also prevention of reintubation. 3 Recently, the Vapotherm 2000i device (VAPO; Vapotherm Inc., Stevensville, MD) was introduced as a high-flow nasal cannula system (HFNC) with high humidity, providing respiratory support to neonates. Vapotherm delivers higher flow rates with increased comfort to the patient. 4 Although there are some published reports of VAPO use in adults, few studies have been conducted in premature infants. Observational studies and anecdotal reports on small numbers of premature infants have suggested the safety of VAPO 5 and effective transition from the ventilator to VAPO, 6 with the existence of limited data.
There has been increased use of VAPO in nurseries presumably because of anecdotal reports and experience that it is easy to use, and well tolerated by the infants, while experiencing decreased nasal septum erosion. However, there are no published trials to date to support or refute these perceptions. Moreover, it is being used as an alternative to NCPAP treatment. Because of the paucity of pulmonary mechanics data in the preterm neonate on VAPO, there is again very little in the literature to support this increased use.
The purpose of this study was to compare the work of breathing (WOB) in a group of premature infants treated with HFNC and NCPAP.
Materials and methods
The study was conducted in the 39-bed, level III NICU at Cooper University Hospital in Camden, New Jersey. The study was approved by the Institutional Review Board and signed informed consent was obtained from parent(s) or guardian(s) before the study.
Preterm infants were eligible for the study if <2.0 kg birth weight and medically stable although requiring NCPAP or HFNC support for mild RDS, chronic lung disease (CLD) and/or apnea of prematurity. The infants were studied on both devices applied in a random order (NCPAP or HFNC), while in a supine position, without sedation, and each infant served as their own control. Nasal continuous positive airway pressure was delivered by connecting Inca nasal prongs (Ackrad Laboratories, Cranford, NJ) to an infant Bird ventilator (VIASYS Healthcare Inc., Conshohocken, PA) set in CPAP mode. The largest prongs that fit the infant's nares without blanching the surrounding tissue were used. High-flow nasal cannula was delivered using the VAPO system, which is capable of providing flow rates of 1 to 8 l/min with a relative humidity of 100%. 7 Data were collected while on VAPO at 3, 4 and 5 l/min (VAPO3, VAPO4 and VAPO5, respectively), and NCPAP at 6 cm H 2 O (NCPAP6) after a stabilization time of approximately 5 mins at each level of flow/pressure. The breaths collected over the last 30 s at each of the levels were used for the analysis.
A detailed description of the data acquisition, validation and analysis was reported previously. [8] [9] [10] Chest wall and abdominal movements were recorded (SomnoStar, Sensormedics Corp., Yorba Linda, CA) in direct current-coupled mode using respiratory inductance plethysmography (RIP) bands (Respibands Plus, Sensormedics Corp., Yorba Linda, CA) placed around the infant's rib cage (RC) and abdomen (ABD). Direct comparison of volume changes measured by face-mask pneumotachography (Hans Rudolph Inc., Kansas City, MO) was used for calibration of the RIP data. Using a linear combination of RC and ABD measurements to compute two calibration coefficients (k 1 and k 2 ), RIP volumes were calculated (V T RIP ¼ k 1 RC þ k 2 ABD). 9 Measurements of tidal esophageal pressure were used to approximate pleural pressures using an esophageal balloon catheter (Viasys Healthcare Inc., Palm Springs, CA). The esophageal balloon catheter was advanced into the esophagus to approximately the lower third of the tracheal length. Proper placement validation was carried out as described previously in detail. [8] [9] [10] [11] Using the Biopac MP100 data acquisition system (Biopac Systems Inc., Santa Barbara, CA), data were sampled at 100 Hz and collected. Calibrated RIP data and transpulmonary pressure (P tp ) changes derived from the esophageal pressure data were used to determine the following respiratory parameters: tidal volume (V T , ml/kg), respiratory rate (RR), lung compliance (C L ), phase angle and end distending pressure. The increase in end distending pressure from baseline (no NCPAP, no HFNC) was determined at NCPAP6 and at each VAPO level. Furthermore, WOB components were calculated using V T RIP and P tp data as described previously, [8] [9] [10] [11] according to the standard Campbell's diagram 12 as shown in Figure 1 . As WOB is altered by patients' variations in tidal volume amplitudes, standardization was done by normalizing WOB by V T .
Because each infant was his/her own control, a pairwise comparison of the two modes of support was performed using a paired t-test. Data were compared between NCPAP at 6 cm H 2 O and VAPO at 3, 4 and 5 l/min. P <0.05 was considered to be statistically significant.
Results
Eighteen preterm neonates were enrolled and studied on both VAPO and NCPAP. Patient demographics are shown in Table 1 . Inspiratory, elastic and resistive WOB (WOB insp, WOB elast and RWOB) at all device settings are shown in Figure 2 . No significant differences were found in WOB insp , WOB elast and RWOB between NCPAP 6 cm H 2 O and VAPO 3, 4 and 5 l/min. Compliance and phase angle (Table 2) were also similar on the VAPO and NCPAP settings. There was a trend of increased compliance with increasing VAPO flow but it was only statistically significant at VAPO of 5 l/min (P ¼ 0.03). Furthermore, there were no differences in the tidal volume and respiratory rate between the VAPO and NCPAP devices ( Table 2 ). The increase in end distending pressure from baseline (no NCPAP, no HFNC) was also determined at each setting ( Figure 3) . The pressures did not vary significantly over all device settings except at VAPO5 (P ¼ 0.03, for NCPAP 6 cm H 2 O compared to VAPO 5 l/min) and the mean increase in pressure from baseline was below 2 cm H 2 O. Figure 1 Example for pressure-volume (P-V) loop used to illustrate work of breathing (WOB) components and method of WOB calculation according to the standard Campbell's diagram. WOB insp (equivalent to area subtended by inspiratory (or upper) limb of P-V loop) is the algebraic sum of WOB elast and inspiratory resistive WOB (RWOB i ). Area within P-V loop is equal to RWOB expended during both inspiration and expiration. WOB elast was estimated as the area subtended by the straight line connecting start and end inspiratory points. 
Discussion
Nasal continuous positive airway pressure is used as an alternative to mechanical ventilation when possible, to treat mild RDS, as respiratory support after extubation, and in the management of apnea of prematurity. Nasal continuous positive airway pressure has been shown to increase functional residual capacity, improve oxygenation and decrease the rate of CLD.
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The Vapotherm 2000i is a respiratory therapy device that allows high-flow rates (up to 8 l/min in infants) of breathing gases to be delivered by a type of nasal cannula (NC), using patented membrane technology to warm and saturate the gas stream. 15 Despite the lack of large controlled trials, and only small case reports or anecdotal impressions available in the literature, VAPO has been used as an alternative to NCPAP with the assumption of comparable respiratory support.
Lain et al. 16 reported that HFNC (5 to 40 l/min), humidified gas delivered by using the VAPO device was well tolerated by adults and concluded that VAPO decreased respiratory rates, increased oxygen saturation, added small amounts of positive end expiratory pressure and may decrease WOB. However, little data are available on pulmonary mechanics in premature infants on HFNC.
No significant increase in intrathoracic pressure was shown in an adult study, whereas maintenance of oxygen content was confirmed. 16 Safety of VAPO was suggested in premature infants using 1 to 3.5 l/min, preventing reintubation. 5 High-flow nasal cannula using VAPO was shown to be as effective as NCPAP in the treatment of RDS in 13 infants requiring respiratory support. 17 
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6 reported 109 preterm infants using VAPO with flow rates of 2 to 8 l/min without evidence of barotrauma, 'CPAP belly', nosocomial infection or nasal mucus plugging.
At present, the literature does not contain any pulmonary mechanics data in premature infants treated with VAPO. Data are limited to small case reports describing safety and efficacy. Our study is the first of its kind to measure pulmonary mechanics on premature infants treated with HFNC using VAPO. These data show no significant difference in WOB when comparing NCPAP of 6 cm VAPO used at 3, 4 and 5 l/min did not show significant differences for all the WOB data and other respiratory parameters. One might postulate that with increased flow, the infants would receive more support. We speculate that the lack of change in the WOB may reflect the relatively mild respiratory disease, and/or that the small increase in VAPO support (from 3 to 5 l/min) may not have been high enough to show significant differences. In this small heterogeneous study population of 18 babies, only ten had been on ventilatory support and nine had been treated with surfactant.
Questions have been posed regarding the amount of pressure delivered by the HFNC amid concerns of overdistention and potential harm from pneumothoraces. Chang et al., 18 in a bench study, measured the temperature, pressure, resistance and humidity with changes in VAPO, NCPAP and NC. This group found significantly elevated delivered pressure with increased levels of VAPO flow (VAPO>NC>NCPAP).
No data have been reported in the literature on the pressures delivered to premature infants treated with VAPO. In our study, the measured esophageal pressure was used to approximate the end distending pressure, which should reflect changes in lung volume. Locke et al. 19 and Sreenan et al., 20 by using esophageal pressures, demonstrated measurable distending pressures when using NC flow.
Our results showed the mean increase in end distending pressure at NCPAP6, VAPO3, VAPO4 and VAPO5 to be 1.76±1.46, 1.22±0.95, 1.60±0.99 and 1.32±0.77 cm H 2 O, respectively ( Figure 3) . The wide distribution of the pressure data may be owing to the heterogeneity of the patient population and the demographics, as shown previously in other related studies reporting changes in lung volumes 10 and lung mechanics. 8 The changes in end distending pressures were only significant at VAPO5 when compared to NCPAP6, and the distending pressures changed only minimally with increasing levels of VAPO. We speculate that this lack of change in pressure at increasing VAPO levels is dependent on the baseline compliance, the respiratory needs and the severity of the infant's respiratory illness. Locke et al. 19 determined that positive distending pressure is also affected by the interaction of the NC, gas flow rate and the anatomy of the infant's airway. Furthermore, in our study, the area of the VAPO NC was 5.07 mm 2 , whereas the average area for the infants' nostrils was 13.40 mm 2 . This would account for leaks around the cannula that would result in minimal changes in the distending pressure and ease the safety concerns that have been posed by clinicians.
At the present time, Vapotherm has instituted a voluntary recall of the Vapotherm 2000i humidification devices in clinical use owing to colonization with Ralstonia species. The source of this contamination is unknown and still under investigation. This recall process has been undertaken in order to conduct high-level disinfection processes for potentially contaminated units and these results will be published in the Mortality and Morbidity Weekly Report.
In conclusion, in the patients studied, there were no differences in the WOB, and no increase in end distending pressures when comparing NCPAP6 and HFNC. We speculate that HFNC using VAPO is providing support comparable to NCPAP6 for these infants with mild respiratory requirements. Our study evaluated only VAPO flow rates of 3, 4 and 5 l/min. A larger study with higher flow rates needs to be undertaken, as VAPO of up to 8 l/min has been used in clinical practice. In our study, the data were collected over a short time period of VAPO support; therefore, additional research is necessary to study its long-term effects. Further large-scale, randomized outcome trials are also needed to evaluate this new therapy along with the effects of HFNC on duration of supplemental oxygen, length of hospital stay, rates of CLD, infection and complications of pneumothoraces. Until such time, HFNC should be used with caution.
